NasdaqGM:ADMA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	472	144	135	139	3
12/31/2025	414	127	107	121	4
12/31/2024	358	83	76	81	4
3/31/2024	283	-4	16	21	N/A
12/31/2023	258	-28	4	9	N/A
9/30/2023	234	-23	-23	-16	N/A
6/30/2023	208	-40	-51	-41	N/A
3/31/2023	182	-48	-61	-48	N/A
12/31/2022	154	-66	-73	-60	N/A
9/30/2022	130	-70	-99	-86	N/A
6/30/2022	110	-73	-99	-86	N/A
3/31/2022	94	-78	-119	-105	N/A
12/31/2021	81	-72	-126	-112	N/A
9/30/2021	69	-74	-125	-111	N/A
6/30/2021	58	-74	-135	-122	N/A
3/31/2021	48	-75	-124	-111	N/A
12/31/2020	42	-76	-115	-102	N/A
9/30/2020	40	-67	-100	-89	N/A
6/30/2020	37	-61	-99	-89	N/A
3/31/2020	36	-54	-92	-87	N/A
12/31/2019	29	-48	-80	-76	N/A
9/30/2019	21	-56	-78	-75	N/A
6/30/2019	18	-59	-66	-64	N/A
3/31/2019	16	-61	-62	-61	N/A
12/31/2018	17	-66	-65	-63	N/A
9/30/2018	18	-61	-61	-57	N/A
6/30/2018	18	-61	-58	-54	N/A
3/31/2018	17	-55	-52	-48	N/A
12/31/2017	16	-44	N/A	-37	N/A
9/30/2017	14	-35	N/A	-28	N/A
6/30/2017	12	-24	N/A	-22	N/A
3/31/2017	11	-21	N/A	-18	N/A
12/31/2016	11	-20	N/A	-18	N/A
9/30/2016	10	-20	N/A	-19	N/A
6/30/2016	9	-20	N/A	-17	N/A
3/31/2016	8	-19	N/A	-16	N/A
12/31/2015	7	-18	N/A	-15	N/A
9/30/2015	6	-17	N/A	-14	N/A
6/30/2015	6	-15	N/A	-14	N/A
3/31/2015	6	-15	N/A	-14	N/A
12/31/2014	6	-17	N/A	-15	N/A
9/30/2014	5	-18	N/A	-15	N/A
6/30/2014	5	-17	N/A	-15	N/A
3/31/2014	4	-18	N/A	-13	N/A
12/31/2013	3	-16	N/A	-11	N/A
9/30/2013	3	-13	N/A	-10	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ADMAは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: ADMA今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ADMA今後 3 年以内に収益を上げることが予想されます。

収益対市場: ADMAの収益 ( 13% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: ADMAの収益 ( 13% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ADMAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

ADMA Biologics 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

Forecast to breakeven in 2024

ADMA Biologics, Inc. Revises Earnings Guidance for the Full Year 2024 and 2025

ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025

Price target increased by 15% to US$6.88

ADMA Biologics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023, Fiscal Year 2024-2025

Recent updates

Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?

ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

Giving ADMA Biologics A Well-Deserved 'Booyah'

Forecast to breakeven in 2024

ADMA Biologics, Inc. Revises Earnings Guidance for the Full Year 2024 and 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares

ADMA Biologics, Inc. to Report Q1, 2024 Results on May 09, 2024

ADMA Biologics, Inc., Annual General Meeting, Jun 04, 2024

Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)

Adma Biologics, Inc. Announces FDA Approvals of Extended Room Temperature Storage Conditions for Asceniv & Bivigam

Full year 2023 earnings: EPS misses analyst expectations

ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025

ADMA Biologics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Price target increased by 15% to US$6.88

ADMA Biologics: On A Roll Entering 2024

Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

ADMA Biologics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023, Fiscal Year 2024-2025

ADMA Biologics, Inc. Announces FDA Approval for BIVIGAM in the Pediatric Patient Setting for Those 2 Years of Age and Older

ADMA Biologics, Inc. Receives FDA Approval for Its Tenth Plasma Collection Center, Located in Laurel, MD

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ADMA Biologics, Inc. Updates Financial Guidance for the Years 2023, 2024 and 2025

ADMA Biologics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Co-Founder & Vice Chairman of the Board recently bought US$482k worth of stock

Executive VP recently sold US$973k worth of stock

Co-Founder notifies of intention to sell stock

Price target increased by 20% to US$6.00

ADMA Biologics, Inc. Updates Earnings Guidance for the Full Year 2023, 2024 and 2025

ADMA Biologics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

ADMA Biologics, Inc Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ADMA Biologics, Inc. Provides Financial Guidance for the Year 2023 and 2024-2025

ADMA Biologics, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

ADMA Biologics, Inc. Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA

Adma Biologics, Inc. Provides Earnings Guidance for the Full Year 2023

Price target increased to US$5.13

ADMA Biologics, Inc. Announces FDA Approval for Room Temperature Storage of Asceniv™ & Bivigam®

ADMA Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $59.999997 million.

ADMA Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $59.999997 million.

ADMA Biologics, Inc. Announces Revenue Guidance for the Quarter and Year Ending December 31, 2022

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Price target increased to US$5.00

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

ADMA Biologics, Inc. Revises Revenue Guidance for the Full Year 2022

No longer forecast to breakeven

ADMA Biologics, Inc. to Report Q3, 2022 Results on Nov 09, 2022

ADMA Biologics, Inc. Receives FDA Approval for Its Seventh Plasma Collection Center, Located in Greensboro, NC

No longer forecast to breakeven

ADMA Biologics: Strong Growth Is Clearing The Path To Profitability

Forecast to breakeven in 2024

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ADMA Biologics, Inc. Provides Earnings Guidance for the Fiscal Year 2022 and 2024

ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M

ADMA Biologics, Inc. to Report Q2, 2022 Results on Aug 10, 2022

ADMA Biologics, Inc. Receives FDA Approval for its Sixth Plasma Collection Center, Located in Myrtle Beach, SC

ADMA Biologics BioCenters Receives FDA Approval for its Sixth Plasma Collection Center, Located in Myrtle Beach, SC

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

ADMA Biologics, Inc. Provides Revenue Guidance for the Remainder of 2022

ADMA Biologics: A Path To Profits Looks Clear

ADMA Biologics, Inc. Revises Earnings Guidance for the Year 2022

ADMA Biologics, Inc. to Report Q1, 2022 Results on May 11, 2022